Clinical Trial Update: Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

View source ↗

Summary

Australian retrospective analysis of patients with EGFR-mutant advanced or metastatic non-small cell lung cancer treated with first- or second-line osimertinib.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED